ArticleItalian journal of pediatrics2026
Association of doxycycline treatment with time to first documented MP-RNA negative conversion in pediatric Mycoplasma pneumoniae pneumonia: a retrospective cohort study.
Article in Italian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMacrolide-resistant Mycoplasma pneumoniae (MRMP) complicates the treatment of pediatric M. pneumoniae pneumonia (MPP). We evaluated whether treatment with doxycycline, compared with azithromycin, was associated with faster first documented negative conversion of M. pneumoniae RNA (MP-RNA) and clinical recovery during a period of high macrolide resistance prevalence.
methodsThis retrospective cohort study included 137 children hospitalized with MPP between October 2023 and January 2025 who received azithromycin (n = 90) or doxycycline (n = 47) monotherapy initiated on admission. MP-RNA was monitored using simultaneous amplification and testing. The primary endpoint was the time from the first antibiotic dose to first documented MP-RNA negative conversion. Multivariable Cox regression, propensity score overlap weighting, and an approximate interval-censored Weibull accelerated failure time model were used.
resultsThe doxycycline group was older and had greater baseline disease severity. The median time to first documented MP-RNA negative conversion was shorter with doxycycline than with azithromycin (6.0 vs. 10.0 days; P < 0.001). Doxycycline use was associated with faster negative conversion in the multivariable Cox model (summary HR 9.28, 95% CI 5.02-17.17; P < 0.001). After overlap weighting, 19 of 20 covariates met the balance threshold, although residual age imbalance remained (absolute SMD = 0.164); the association persisted (summary HR 8.08, 95% CI 4.27-15.31; P < 0.001). The interval-censored model yielded a time ratio of 0.60 (95% CI 0.53-0.67; P < 0.001). The 24-hour rapid defervescence rate was 89.4% with doxycycline and 37.8% with azithromycin (risk difference 51.6%, 95% CI 36.3%-63.4%). No severe treatment-limiting adverse events were documented. Among 24 doxycycline-treated children aged < 8 years, no tooth discoloration or enamel hypoplasia was reported during follow-up, although dental assessment was not standardized.
conclusionsDoxycycline use was associated with faster first documented MP-RNA negative conversion and clinical recovery than azithromycin. These retrospective, nonrandomized findings do not establish causal superiority. Doxycycline may be considered when macrolide resistance is confirmed or strongly suspected, but prospective multicenter studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.